2
|
Hofer DC, Zirkovits G, Pelzmann HJ, Huber K, Pessentheiner AR, Xia W, Uno K, Miyazaki T, Kon K, Tsuneki H, Pendl T, Al Zoughbi W, Madreiter-Sokolowski CT, Trausinger G, Abdellatif M, Schoiswohl G, Schreiber R, Eisenberg T, Magnes C, Sedej S, Eckhardt M, Sasahara M, Sasaoka T, Nitta A, Hoefler G, Graier WF, Kratky D, Auwerx J, Bogner-Strauss JG. N-acetylaspartate availability is essential for juvenile survival on fat-free diet and determines metabolic health. FASEB J 2019; 33:13808-13824. [PMID: 31638418 PMCID: PMC6894082 DOI: 10.1096/fj.201801323r] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2018] [Accepted: 09/10/2019] [Indexed: 12/15/2022]
Abstract
N-acetylaspartate (NAA) is synthesized by aspartate N-acetyltransferase (gene: Nat8l) from acetyl-coenzyme A and aspartate. In the brain, NAA is considered an important energy metabolite for lipid synthesis. However, the role of NAA in peripheral tissues remained elusive. Therefore, we characterized the metabolic phenotype of knockout (ko) and adipose tissue-specific (ako) Nat8l-ko mice as well as NAA-supplemented mice on various diets. We identified an important role of NAA availability in the brain during adolescence, as 75% of Nat8l-ko mice died on fat-free diet (FFD) after weaning but could be rescued by NAA supplementation. In adult life, NAA deficiency promotes a beneficial metabolic phenotype, as Nat8l-ko and Nat8l-ako mice showed reduced body weight, increased energy expenditure, and improved glucose tolerance on chow, high-fat, and FFDs. Furthermore, Nat8l-deficient adipocytes exhibited increased mitochondrial respiration, ATP synthesis, and an induction of browning. Conversely, NAA-treated wild-type mice showed reduced adipocyte respiration and lipolysis and increased de novo lipogenesis, culminating in reduced energy expenditure, glucose tolerance, and insulin sensitivity. Mechanistically, our data point to a possible role of NAA as modulator of pancreatic insulin secretion and suggest NAA as a critical energy metabolite for adipocyte and whole-body energy homeostasis.-Hofer, D. C., Zirkovits, G., Pelzmann, H. J., Huber, K., Pessentheiner, A. R., Xia, W., Uno, K., Miyazaki, T., Kon, K., Tsuneki, H., Pendl, T., Al Zoughbi, W., Madreiter-Sokolowski, C. T., Trausinger, G., Abdellatif, M., Schoiswohl, G., Schreiber, R., Eisenberg, T., Magnes, C., Sedej, S., Eckhardt, M., Sasahara, M., Sasaoka, T., Nitta, A., Hoefler, G., Graier, W. F., Kratky, D., Auwerx, J., Bogner-Strauss, J. G. N-acetylaspartate availability is essential for juvenile survival on fat-free diet and determines metabolic health.
Collapse
Affiliation(s)
- Dina C. Hofer
- Institute of Biochemistry, Graz University of Technology, Graz, Austria
- Laboratory of Integrative and Systems Physiology, Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
| | - Gabriel Zirkovits
- Institute of Biochemistry, Graz University of Technology, Graz, Austria
| | - Helmut J. Pelzmann
- Institute of Biochemistry, Graz University of Technology, Graz, Austria
- Fresenius Kabi Austria GmbH, Graz, Austria
| | - Katharina Huber
- Institute of Biochemistry, Graz University of Technology, Graz, Austria
- Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland
| | - Ariane R. Pessentheiner
- Institute of Biochemistry, Graz University of Technology, Graz, Austria
- Department of Medicine, University of California–San Diego, La Jolla, California, USA
| | - Wenmin Xia
- Institute of Biochemistry, Graz University of Technology, Graz, Austria
| | - Kyosuke Uno
- Department of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan
| | - Toh Miyazaki
- Department of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan
| | - Kanta Kon
- Department of Clinical Pharmacology, University of Toyama, Toyama, Japan
| | - Hiroshi Tsuneki
- Department of Clinical Pharmacology, University of Toyama, Toyama, Japan
| | - Tobias Pendl
- Institute of Molecular Biosciences, NAWI Graz, University of Graz, Graz, Austria
| | - Wael Al Zoughbi
- Institute of Pathology, Medical University of Graz, Graz, Austria
| | | | - Gert Trausinger
- Joanneum Research, HEALTH–Institute for Biomedicine and Health Sciences, Graz, Austria
| | | | | | - Renate Schreiber
- Institute of Molecular Biosciences, University of Graz, Graz, Austria
| | - Tobias Eisenberg
- Institute of Molecular Biosciences, NAWI Graz, University of Graz, Graz, Austria
- BioTechMed-Graz, Graz, Austria
| | - Christoph Magnes
- Joanneum Research, HEALTH–Institute for Biomedicine and Health Sciences, Graz, Austria
| | - Simon Sedej
- Department of Cardiology, Medical University of Graz, Graz, Austria
- BioTechMed-Graz, Graz, Austria
| | - Matthias Eckhardt
- Institute of Biochemistry and Molecular Biology, University of Bonn, Bonn, Germany
| | | | - Toshiyasu Sasaoka
- Department of Clinical Pharmacology, University of Toyama, Toyama, Japan
| | - Atsumi Nitta
- Department of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan
| | - Gerald Hoefler
- Institute of Pathology, Medical University of Graz, Graz, Austria
| | - Wolfgang F. Graier
- Gottfried Schatz Research Center, Medical University of Graz, Graz, Austria
- BioTechMed-Graz, Graz, Austria
| | - Dagmar Kratky
- Gottfried Schatz Research Center, Medical University of Graz, Graz, Austria
- BioTechMed-Graz, Graz, Austria
| | - Johan Auwerx
- Laboratory of Integrative and Systems Physiology, Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
| | - Juliane G. Bogner-Strauss
- Institute of Biochemistry, Graz University of Technology, Graz, Austria
- BioTechMed-Graz, Graz, Austria
| |
Collapse
|
4
|
Machado C, Estevez M, Perez-Nellar J, Schiavi A. Residual vasomotor activity assessed by heart rate variability in a brain-dead case. BMJ Case Rep 2015; 2015:bcr-2014-205677. [PMID: 25833905 DOI: 10.1136/bcr-2014-205677] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
A patient assessed by heart rate variability (HRV) methodology, beginning just after the completion of brain death (BD) diagnosis, showed remaining very low frequency (VLF) waves for approximately 10 min. A time-varying spectral analysis showed that during the first 550 s, a significant power spectral density remained in the high-frequency (HF), low-frequency (LF) and VLF bands. From 550 to 675 s, the HF oscillations totally vanished, and a marked progressive decay of the LF and VLF power density occurred. After 700 s the VLF undulations stopped and remaining small amplitude oscillations at 0.2 Hz coincided with the ventilator frequency. The VLF oscillations recorded in our case might be related to residual sympathetic vasomotor activity that progressively disappeared due to the extension of necrosis affecting the nervous centres of the lower part of the medulla and the first 2-3 cervical spine segments.
Collapse
Affiliation(s)
- Calixto Machado
- Department of Clinical Neurophysiology, Institute of Neurology and Neurosugery, Havana, Cuba
| | | | | | - Adam Schiavi
- Anesthesiology and Critical Care Medicine, Neurosciences Critical Care Division, Johns Hopkins Hospital, Baltimore, Maryland, USA
| |
Collapse
|